Logo image of MRSN

MERSANA THERAPEUTICS INC (MRSN) Stock Price, Quote, News and Overview

NASDAQ:MRSN - Nasdaq - US59045L1061 - Common Stock - Currency: USD

0.3639  +0 (+0.44%)

After market: 0.3637 0 (-0.05%)

MRSN Quote, Performance and Key Statistics

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (4/25/2025, 8:24:40 PM)

After market: 0.3637 0 (-0.05%)

0.3639

+0 (+0.44%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High3.63
52 Week Low0.26
Market Cap45.35M
Shares124.63M
Float122.75M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/bmo
IPO06-28 2017-06-28


MRSN short term performance overview.The bars show the price performance of MRSN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40 -60 -80

MRSN long term performance overview.The bars show the price performance of MRSN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of MRSN is 0.3639 USD. In the past month the price decreased by -2.23%. In the past year, price decreased by -87.62%.

MERSANA THERAPEUTICS INC / MRSN Daily stock chart

MRSN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.39 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 330.52 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About MRSN

Company Profile

MRSN logo image Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

Company Info

MERSANA THERAPEUTICS INC

840 Memorial Dr

Cambridge MASSACHUSETTS 02139 US

CEO: Anna Protopapas

Employees: 123

Company Website: https://www.mersana.com/

Investor Relations: https://ir.mersana.com/

Phone: 16174980020

MERSANA THERAPEUTICS INC / MRSN FAQ

What is the stock price of MERSANA THERAPEUTICS INC today?

The current stock price of MRSN is 0.3639 USD. The price increased by 0.44% in the last trading session.


What is the ticker symbol for MERSANA THERAPEUTICS INC stock?

The exchange symbol of MERSANA THERAPEUTICS INC is MRSN and it is listed on the Nasdaq exchange.


On which exchange is MRSN stock listed?

MRSN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MERSANA THERAPEUTICS INC stock?

15 analysts have analysed MRSN and the average price target is 4.93 USD. This implies a price increase of 1254.76% is expected in the next year compared to the current price of 0.3639. Check the MERSANA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MERSANA THERAPEUTICS INC worth?

MERSANA THERAPEUTICS INC (MRSN) has a market capitalization of 45.35M USD. This makes MRSN a Nano Cap stock.


How many employees does MERSANA THERAPEUTICS INC have?

MERSANA THERAPEUTICS INC (MRSN) currently has 123 employees.


What are the support and resistance levels for MERSANA THERAPEUTICS INC (MRSN) stock?

MERSANA THERAPEUTICS INC (MRSN) has a support level at 0.32 and a resistance level at 0.39. Check the full technical report for a detailed analysis of MRSN support and resistance levels.


Is MERSANA THERAPEUTICS INC (MRSN) expected to grow?

The Revenue of MERSANA THERAPEUTICS INC (MRSN) is expected to decline by -3.73% in the next year. Check the estimates tab for more information on the MRSN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MERSANA THERAPEUTICS INC (MRSN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MERSANA THERAPEUTICS INC (MRSN) stock pay dividends?

MRSN does not pay a dividend.


When does MERSANA THERAPEUTICS INC (MRSN) report earnings?

MERSANA THERAPEUTICS INC (MRSN) will report earnings on 2025-05-12, before the market open.


What is the Price/Earnings (PE) ratio of MERSANA THERAPEUTICS INC (MRSN)?

MERSANA THERAPEUTICS INC (MRSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).


What is the Short Interest ratio of MERSANA THERAPEUTICS INC (MRSN) stock?

The outstanding short interest for MERSANA THERAPEUTICS INC (MRSN) is 7.08% of its float. Check the ownership tab for more information on the MRSN short interest.


MRSN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MRSN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MRSN. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRSN Financial Highlights

Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 60.56% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -47.83%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%31.25%
Sales Q2Q%52.89%
EPS 1Y (TTM)60.56%
Revenue 1Y (TTM)9.89%

MRSN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to MRSN. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -29.84% and a revenue growth -3.73% for MRSN


Ownership
Inst Owners92.18%
Ins Owners1.54%
Short Float %7.08%
Short Ratio2.65
Analysts
Analysts86.67
Price Target4.93 (1254.77%)
EPS Next Y-29.84%
Revenue Next Year-3.73%